124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details
Clinical trials : 12 / Drugs : 14 - (DrugBank : 5) / Drug target genes : 3 - Drug target pathways : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051220072 | 09/08/2022 | 09/08/2022 | Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy | Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy - LOMCAD | Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) CADASIL;D046589 | Lomerizine hydrochloride (MIGSYS tablets 5 mg, 1 tablet twice daily) will be administered continuously for 24 months as the study drug. | Mizuno Toshiki | NULL | Recruiting | >= 20age old | <= 70age old | Both | 20 | N/A | Japan |